OnKure Therapeutics, Inc. (OKUR) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.01
+6% vs avg
5yr avg: 0.95
30Y Low0.7·High1.1
ROE
↑
-74.4%
↓+95% vs avg
5yr avg: -1379.5%
30Y Low-76%·High-64%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OKUR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
OnKure Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $57M | $39M | $115M | $213M | $311M | $155M | — |
| Enterprise Value | $-1071880 | $-19304847 | $5M | $184M | $300M | $30M | — |
| P/E Ratio → | -0.95 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 1.01 | 0.70 | 1.10 | — | — | 1.05 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
OKUR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
OKUR Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -74.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -74.4% | -74.4% | -5304.4% | — | -63.6% | -75.7% | — |
| ROA | -67.2% | -67.2% | -69.9% | -136.5% | -34.7% | -38.0% | -35.2% |
| ROIC | — | — | — | — | — | -305.6% | — |
| ROCE | -78.4% | -78.4% | -81.9% | -189.9% | -37.6% | -40.1% | -38.6% |
OKUR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $59M exceeds total debt of $549000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.04 | -1.06 | — | — | -0.85 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -174.58 | — | — | — | — |
Net cash position: cash ($59M) exceeds total debt ($549000)
OKUR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
OnKure Therapeutics, Inc.'s current ratio of 10.28x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.64x to 10.28x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 10.28 | 10.28 | 10.73 | 4.64 | 2.46 | 24.79 | 12.01 |
| Quick Ratio | 10.28 | 10.28 | 10.73 | 4.64 | 2.46 | 24.79 | 12.01 |
| Cash Ratio | 9.97 | 9.97 | 10.52 | 4.10 | 2.08 | 23.81 | 11.71 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
OKUR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
OnKure Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $14M | $13M | $13M | $13M | $2M | $3M |
Peer Comparison
Compare OKUR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OKURYou | $57M | -1.0 | — | — | — | — | -74.4% | — | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARVN | $489M | -5.9 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 TNGX | $4B | -35.6 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 AUPH | $2B | 7.6 | 17.8 | 15.0 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 RCUS | $2B | -7.2 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ERAS | $4B | -31.9 | — | — | — | — | -33.3% | -27.9% | — |
 PMVP | $59M | -0.8 | — | — | — | — | -55.4% | -63.4% | — |
 CRL | $9B | -64.4 | 13.0 | 17.4 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
What if you invested $1,000 in OKUR 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in OKUR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs OKUR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationOKUR vs KYMR — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Kymera Therapeutics, Inc..
Compare NowOKUR — Frequently Asked Questions
Quick answers to the most common questions about buying OKUR stock.
What is OnKure Therapeutics, Inc.'s P/E ratio?
OnKure Therapeutics, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
What is OnKure Therapeutics, Inc.'s ROE?
OnKure Therapeutics, Inc.'s return on equity (ROE) is -74.4%. The historical average is -71.2%.
Is OKUR stock overvalued?
Based on historical data, OnKure Therapeutics, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.